{"id":"paricalcitol-atorvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1200622","moleculeType":"Small molecule","molecularWeight":"416.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paricalcitol is a selective vitamin D receptor activator that regulates calcium and phosphate homeostasis, particularly useful in chronic kidney disease. Atorvastatin is a statin that reduces LDL cholesterol by inhibiting hepatic cholesterol synthesis. Together, they address both mineral-bone metabolism and cardiovascular risk in patients with kidney disease.","oneSentence":"This combination uses paricalcitol to activate vitamin D receptors for mineral metabolism regulation and atorvastatin to inhibit HMG-CoA reductase for cholesterol lowering.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:36.547Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in chronic kidney disease patients with dyslipidemia"}]},"trialDetails":[{"nctId":"NCT01820767","phase":"PHASE3","title":"Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients","status":"COMPLETED","sponsor":"Ricardo Mouzo Mirco","startDate":"2012-08","conditions":"Chronic Kidney Disease","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["G2"],"phase":"phase_3","status":"active","brandName":"Paricalcitol, atorvastatin","genericName":"Paricalcitol, atorvastatin","companyName":"Ricardo Mouzo Mirco","companyId":"ricardo-mouzo-mirco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses paricalcitol to activate vitamin D receptors for mineral metabolism regulation and atorvastatin to inhibit HMG-CoA reductase for cholesterol lowering. Used for Secondary hyperparathyroidism in chronic kidney disease patients with dyslipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}